Table 3.

Retention of the Study Participants for IL-6 and 400 m Walk Assessments, and Effect of Losartan, Fish Oil, and Combination of Losartan + Fish Oil on IL-6 and 400 m Walk Speed

		Losartan			Fish Oil
	Month	Active N = 65 N (%)	Placebo N = 44 N (%)	Effect ± SE (95% CI); p-value	Active N = 148 N (%)	Placebo N = 98 N (%)	Effect (SE), 95% CI: p-value
Natural log of il6	3	58 (89.2%)	40 (90.9%)	−0.152 ± 0.096 (−0.342, 0.038); p = .12	137 (92.6%)	92 (93.9%)	0.098 ± 0.063 (−0.026, 0.222); p = .12
	6	57 (87.7%)	37 (84.1%)	−0.201 ± 0.116 (−0.429, 0.026); p = .08	134 (90.5%)	87 (88.8%)	0.019 ± 0.075 (−0.130, 0.167); p = .80
	9	52 (80.0%)	34 (77.3%)	0.047 ± 0.114 (−0.178, 0.271); p = .68	130 (87.8%)	78 (79.6%)	0.044 ± 0.074 (−0.102, 0.190); p = .55
	12	54 (83.1%)	37 (84.1%)	−0.065 ± 0.116 (−0.293, 0.163); p = .58	129 (87.2%)	80 (81.6%)	−0.020 ± 0.077 (−0.171, 0.132); p = .80
	Average			−0.093 ± 0.081 (−0.253, 0.067); p = .26			0.035 ± 0.053 (−0.069, 0.140); p = .51
400 m walking speed	3	54 (83.1%)	37 (84.1%)	0.016 ± 0.020 (−0.023, 0.055); p = .43	131 (88.5%)	86 (87.8%)	0.005 ± 0.013 (−0.021, 0.030); p = .72
	6	51 (78.5%)	33 (75.0%)	0.009 ± 0.021 (−0.033, 0.051); p = .68	122 (82.4%)	79 (80.6%)	0.019 ± 0.014 (−0.008, 0.047); p = .17
	9	48 (73.8%)	30 (68.2%)	−0.030 ± 0.026 (−0.082, 0.022); p = .26	115 (77.7%)	72 (73.5%)	0.013 ± 0.017 (−0.021, 0.047); p = .45
	12	44 (67.7%)	34 (77.3%)	−0.025 ± 0.026 (−0.076, 0.026); p = .34	113 (76.4%)	67 (68.4%)	0.010 ± 0.017 (−0.025, 0.044); p = .58
	Average			−0.007 ± 0.020 (−0.048, 0.033); p = .71			0.012 ± 0.013 (−0.015, 0.038); p = .39